Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

C. Roux*, D. M. Reid, J. P. Devogelaer, K. Saag, C. S. Lau, J. Y. Reginster, P. Papanastasiou, C. Bucci-Rechtweg, G. Su, P. N. Sambrook

*Corresponding author for this work

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Zoledronic acid is significantly more effective than risedronate in increasing lumbar spine (LS) bone mineral density (BMD) in both prevention and treatment of glucocorticoid-induced osteoporosis. Introduction: In patients on glucocorticoids, a single zoledronic acid infusion significantly increased BMD versus daily oral risedronate. We assessed treatment effect on LS BMD in different patient subgroups at month 12 that contributed to the risk of osteoporosis in addition to glucocorticoids. Methods: Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate (5 mg/day) and stratified based on glucocorticoids duration [treatment (>3 months) and prevention (≤3 months) subpopulations] were subgrouped by age; gender; menopausal status in women; dose and duration of prednisone during the trial; and baseline serum 25-OH vitamin D, LS BMD T-score, creatinine clearance, and concomitant medication use. Results: At month 12, zoledronic acid significantly increased LS BMD versus risedronate in patients ≤74 years (P < 0.05) in the treatment and 65-74 years (P = 0.0008) in the prevention subpopulation. At month 12, zoledronic acid significantly increased LS BMD versus risedronate in both subpopulations irrespective of gender (all P < 0.05), cumulative prednisone dose (all P < 0.01), and postmenopausal status (all P < 0.05). In premenopausal women, in both subpopulations, zoledronic acid significantly increased total hip BMD (all P < 0.05) versus risedronate at month 12 but not LS BMD. Osteoporotic patients in the prevention (P = 0.0189) and osteopenic patients in the treatment subpopulation (P = 0.0305) showed significant LS BMD increases with zoledronic acid versus risedronate at month 12. Conclusions: This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients

Original languageEnglish
Pages (from-to)1083-1090
Number of pages8
JournalOsteoporosis International
Volume23
Issue number3
DOIs
Publication statusPublished - 1 Mar 2012

Fingerprint

zoledronic acid
Bone Density
Glucocorticoids
Osteoporosis
Spine
Prednisone
Therapeutics
Risedronate Sodium
Pelvic Bones

Keywords

  • Bone mineral density
  • Glucocorticoids
  • Osteoporosis
  • Risedronate
  • Zoledronic acid

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. / Roux, C.; Reid, D. M.; Devogelaer, J. P.; Saag, K.; Lau, C. S.; Reginster, J. Y.; Papanastasiou, P.; Bucci-Rechtweg, C.; Su, G.; Sambrook, P. N.

In: Osteoporosis International, Vol. 23, No. 3, 01.03.2012, p. 1083-1090.

Research output: Contribution to journalArticle

Roux, C. ; Reid, D. M. ; Devogelaer, J. P. ; Saag, K. ; Lau, C. S. ; Reginster, J. Y. ; Papanastasiou, P. ; Bucci-Rechtweg, C. ; Su, G. ; Sambrook, P. N. / Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. In: Osteoporosis International. 2012 ; Vol. 23, No. 3. pp. 1083-1090.
@article{54b84e1462af47faa0e0fb6c524b555b,
title = "Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis",
abstract = "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Zoledronic acid is significantly more effective than risedronate in increasing lumbar spine (LS) bone mineral density (BMD) in both prevention and treatment of glucocorticoid-induced osteoporosis. Introduction: In patients on glucocorticoids, a single zoledronic acid infusion significantly increased BMD versus daily oral risedronate. We assessed treatment effect on LS BMD in different patient subgroups at month 12 that contributed to the risk of osteoporosis in addition to glucocorticoids. Methods: Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate (5 mg/day) and stratified based on glucocorticoids duration [treatment (>3 months) and prevention (≤3 months) subpopulations] were subgrouped by age; gender; menopausal status in women; dose and duration of prednisone during the trial; and baseline serum 25-OH vitamin D, LS BMD T-score, creatinine clearance, and concomitant medication use. Results: At month 12, zoledronic acid significantly increased LS BMD versus risedronate in patients ≤74 years (P < 0.05) in the treatment and 65-74 years (P = 0.0008) in the prevention subpopulation. At month 12, zoledronic acid significantly increased LS BMD versus risedronate in both subpopulations irrespective of gender (all P < 0.05), cumulative prednisone dose (all P < 0.01), and postmenopausal status (all P < 0.05). In premenopausal women, in both subpopulations, zoledronic acid significantly increased total hip BMD (all P < 0.05) versus risedronate at month 12 but not LS BMD. Osteoporotic patients in the prevention (P = 0.0189) and osteopenic patients in the treatment subpopulation (P = 0.0305) showed significant LS BMD increases with zoledronic acid versus risedronate at month 12. Conclusions: This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients",
keywords = "Bone mineral density, Glucocorticoids, Osteoporosis, Risedronate, Zoledronic acid",
author = "C. Roux and Reid, {D. M.} and Devogelaer, {J. P.} and K. Saag and Lau, {C. S.} and Reginster, {J. Y.} and P. Papanastasiou and C. Bucci-Rechtweg and G. Su and Sambrook, {P. N.}",
note = "Acknowledgement The authors would like to thank the writing and editorial assistance of Jyothi D (Novartis Healthcare Pvt. Ltd).",
year = "2012",
month = "3",
day = "1",
doi = "10.1007/s00198-011-1800-1",
language = "English",
volume = "23",
pages = "1083--1090",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "SPRINGER-VERLAG LONDON LTD",
number = "3",

}

TY - JOUR

T1 - Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

AU - Roux, C.

AU - Reid, D. M.

AU - Devogelaer, J. P.

AU - Saag, K.

AU - Lau, C. S.

AU - Reginster, J. Y.

AU - Papanastasiou, P.

AU - Bucci-Rechtweg, C.

AU - Su, G.

AU - Sambrook, P. N.

N1 - Acknowledgement The authors would like to thank the writing and editorial assistance of Jyothi D (Novartis Healthcare Pvt. Ltd).

PY - 2012/3/1

Y1 - 2012/3/1

N2 - This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Zoledronic acid is significantly more effective than risedronate in increasing lumbar spine (LS) bone mineral density (BMD) in both prevention and treatment of glucocorticoid-induced osteoporosis. Introduction: In patients on glucocorticoids, a single zoledronic acid infusion significantly increased BMD versus daily oral risedronate. We assessed treatment effect on LS BMD in different patient subgroups at month 12 that contributed to the risk of osteoporosis in addition to glucocorticoids. Methods: Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate (5 mg/day) and stratified based on glucocorticoids duration [treatment (>3 months) and prevention (≤3 months) subpopulations] were subgrouped by age; gender; menopausal status in women; dose and duration of prednisone during the trial; and baseline serum 25-OH vitamin D, LS BMD T-score, creatinine clearance, and concomitant medication use. Results: At month 12, zoledronic acid significantly increased LS BMD versus risedronate in patients ≤74 years (P < 0.05) in the treatment and 65-74 years (P = 0.0008) in the prevention subpopulation. At month 12, zoledronic acid significantly increased LS BMD versus risedronate in both subpopulations irrespective of gender (all P < 0.05), cumulative prednisone dose (all P < 0.01), and postmenopausal status (all P < 0.05). In premenopausal women, in both subpopulations, zoledronic acid significantly increased total hip BMD (all P < 0.05) versus risedronate at month 12 but not LS BMD. Osteoporotic patients in the prevention (P = 0.0189) and osteopenic patients in the treatment subpopulation (P = 0.0305) showed significant LS BMD increases with zoledronic acid versus risedronate at month 12. Conclusions: This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients

AB - This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Zoledronic acid is significantly more effective than risedronate in increasing lumbar spine (LS) bone mineral density (BMD) in both prevention and treatment of glucocorticoid-induced osteoporosis. Introduction: In patients on glucocorticoids, a single zoledronic acid infusion significantly increased BMD versus daily oral risedronate. We assessed treatment effect on LS BMD in different patient subgroups at month 12 that contributed to the risk of osteoporosis in addition to glucocorticoids. Methods: Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate (5 mg/day) and stratified based on glucocorticoids duration [treatment (>3 months) and prevention (≤3 months) subpopulations] were subgrouped by age; gender; menopausal status in women; dose and duration of prednisone during the trial; and baseline serum 25-OH vitamin D, LS BMD T-score, creatinine clearance, and concomitant medication use. Results: At month 12, zoledronic acid significantly increased LS BMD versus risedronate in patients ≤74 years (P < 0.05) in the treatment and 65-74 years (P = 0.0008) in the prevention subpopulation. At month 12, zoledronic acid significantly increased LS BMD versus risedronate in both subpopulations irrespective of gender (all P < 0.05), cumulative prednisone dose (all P < 0.01), and postmenopausal status (all P < 0.05). In premenopausal women, in both subpopulations, zoledronic acid significantly increased total hip BMD (all P < 0.05) versus risedronate at month 12 but not LS BMD. Osteoporotic patients in the prevention (P = 0.0189) and osteopenic patients in the treatment subpopulation (P = 0.0305) showed significant LS BMD increases with zoledronic acid versus risedronate at month 12. Conclusions: This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients

KW - Bone mineral density

KW - Glucocorticoids

KW - Osteoporosis

KW - Risedronate

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84857440380&partnerID=8YFLogxK

U2 - 10.1007/s00198-011-1800-1

DO - 10.1007/s00198-011-1800-1

M3 - Article

VL - 23

SP - 1083

EP - 1090

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 3

ER -